$ANNX

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (1m)

-14.1%

Win rate (1m)

0% (1 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 4m ago

$ANNXr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 23h ago31 prior · 63% at 3mo

10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.

ANNX is watching for the Phase 3 topline for ARCHER II, a potential first-in-class geographic-atrophy drug showing vision protection rather than slowing progression. With 89% implied volatility to January and an insider officer buying $100K in late September, the upside binary is substantial.

At post $3.86Now $3.860.0% since posted4m ago

original post →

$ANNXr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 45d ago31 prior · 63% at 3mo

“Watching”

10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.

ARCHER II Phase 3 in geographic atrophy (630+ patients, 2:1 vs sham) targeting vision protection via preventing 15-letter loss—a first if successful, as approved GA drugs only slow lesion growth. Topline due 2H 2026, with strong insider activity and implied volatility around ±96%, but 12.5 months runway creates execution risk if data slips.

At post $4.67Now $3.86-17.3% since posted4m ago

1d—

3d-11.3%

1w-15.4%

1m-14.1%

3m—

6m—

1y—

original post →

End of results.